Top Story

PCSK9 inhibitors: What you should know

July 5, 2015

Proprotein convertase subtilisin/kexin type 9, also known as PCSK9, provides instructions for the body to produce a protein that helps regulate the amount of cholesterol in the bloodstream and appears to control the number of LDL receptors, according to the National Institutes of Health.

Recently, inhibitors of PCSK9 have been developed as potential therapies to reduce LDL levels in patients with elevated cholesterol or inherited cholesterol disorders. Clinical trial data have documented significant LDL reductions in patients with hypercholesterolemia and familial hypercholesterolemia in combination with statins or administered alone, with minimal side effects.

ACC launches Statin Intolerance App

July 4, 2015
The American College of Cardiology has launched a free app designed to aid clinicians in the management and treatment of patients who report adverse muscular symptoms…
FDA News

FDA clears scoring balloon catheters with larger diameter

July 3, 2015
Spectranetics recently announced that it has received FDA 510(k) clearance for a scoring balloon catheter in diameters of 7 mm and 8 mm to treat a narrowed fistula…
In the Journals

Physician urges FDA not to lift restrictions on drug makers’ claims about their products

July 3, 2015
Drug regulations and a governing body to mandate them is a necessity for patients’ safety and health care providers’ peace-of-mind, according to a recently…
Lori C. Jordan, MD, PhD In the Journals

ED rapid response plan helps diagnose pediatric stroke symptoms

July 2, 2015
Among children presenting to the ED of a single center with brain attacks when a pediatric acute stroke protocol was activated, 40% had a stroke or other neurological…
More News Headlines »
Cardiology Case Consults

The Patient with Acute Coronary Syndrome

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with acute coronary syndrome.
More »
Meeting News Coverage Video
VIDEO: Knowledge of supplements and drug interactions essential for HF practitioners

VIDEO: Knowledge of supplements and drug interactions essential for HF practitioners

June 28, 2015
NEW ORLEANS – Joseph Ho, PharmD, clinical pharmacist with Ochsner Baptist Medical Center in New Orleans…
More »
Antiplatelet Agents in ACS Distinguishing Characteristics Safety and Efficacy

Antiplatelet Agents in ACS: Distinguishing Characteristics, Safety, and Efficacy

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »